Relative rate experiments were used to measure ratios of chemical kinetics rate constants as a function of temperature for the reactions of OH with isobutane, isopentane, 2-methylpentane, 3-methylpentane, 2,3-dimethylbutane, 2,3-dimethylpentane, 2,4-dimethylpentane, 2,3,4-trimethylpentane, n-heptane, n-octane, cyclopentane, cyclohexane, and cycloheptane. The results have been used to calibrate a structure-reactivity rate constant estimation method for k(298 K) which, when combined with previously determined relationships between k(298 K) and the Arrhenius parameters, is capable of determining the temperature dependence accurately. The estimation method reproduces most of the observed rate data within experimental accuracy but appears to fail for 2,3-dimethylbutane, which has an anomalously high rate constant. Curvature in the Arrhenius plots at low temperatures is not present for compounds with a single type of C-H bond and, for compounds with different C-H bonds, is shown to be consistent with effects due to different group sites on the molecule.

BackgroundOncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinical trials are not able to assess overall survival and generalises evidence in a real-world setting. As a result, policy makers have little information on whether drug funding decisions based on clinical trials ultimately yield the outcomes and value for money that might be expected.ObjectiveThe Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, consisting of researchers, recommendation-makers, decision makers, payers, patients and caregivers, are developing and testing a framework for Canadian provinces to generate and use real-world evidence (RWE) for cancer drug funding in a consistent and integrated manner.StrategyThe CanREValue collaboration has established five formal working groups (WGs) to focus on specific processes in the generation and use of RWE for cancer drug funding decisions in Canada. The different RWE WGs are: (1) Planning and Drug Selection; (2) Methods; (3) Data; (4) Reassessment and Uptake; (5) Engagement. These WGs are acting collaboratively to develop a framework for RWE evaluation, validate the framework through the multiprovince RWE projects and help to integrate the final RWE framework into the Canadian healthcare system.OutcomesThe framework will enable the reassessment of cancer drugs, refinement of funding recommendations and use of novel funding mechanisms by decision-makers/payers across Canada to ensure the healthcare system is providing clinical benefits and value for money.

No abstract

No abstract

No abstract